Algernon Pharmaceuticals Inc. (C:AGN)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Apr 11, 2024 07:00 am ET

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), is pleased to invite investors and other interested parties to participate in an upcoming special CEO interview and Q & A session on April...

Apr 01, 2024 07:00 am ET

Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it plans to move forward with its intravenous...

Mar 28, 2024 06:40 am ET

Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to announce a significant agreement regarding the company's drug, Ifenprodil with U.S. Based Seyltx. Originally discovered in Japan and not utilized in the US or Europe, Ifenprodil was initially developed to treat intermittent claudication but found application in Japan for vertigo post-stroke. Dr. Mark Williams, Algernon's co-founder, identified Ifenprodil's potential for repurposing in new markets, particularly for Idiopathic Pulmonary Fibrosis (IPF) and chronic cough, a symptom associated with IPF.

Mar 27, 2024 12:18 pm ET

Canadian Investment Regulatory Organization Trade Resumption - AGN

VANCOUVER, BC, March 27, 2024 /CNW/ - Trading resumes in:

Mar 27, 2024 12:04 pm ET

Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Mar 27, 2024 10:37 am ET

Canadian Investment Regulatory Organization Trading Halt - AGN

VANCOUVER, BC, March 27, 2024 /CNW/ - The following issues have been halted by CIRO:

Feb 22, 2024 03:16 pm ET

ALAMO GROUP INC. ANNOUNCES RETIREMENT OF BOARD MEMBER, APPOINTMENT OF NEW BOARD CHAIR AND APPOINTMENT OF NEW DIRECTOR

SEGUIN, Texas, Feb. 22, 2024 /PRNewswire/ -- Alamo Group Inc. (NYSE: ALG) today announced that Roderick ("Rock") R. Baty will retire from the Board of Directors effective April 30, 2024. Mr. Baty joined the Board in August 2011 and has served in various capacities during his tenure. Mr. Baty was appointed Independent Board Chair on May 3, 2018. Upon Mr. Baty's retirement from the Board, current Board member, Richard ("Rick") W. Parod, will be appointed the new Independent Board Chair effective April 30, 2024.

Jan 31, 2024 07:00 am ET

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from...

Jan 11, 2024 07:00 am ET

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company is pleased to announce that it has received a notice of allowance from the Japanese...

Dec 27, 2023 04:01 pm ET

Algernon Pharmaceuticals Announces Closing of Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on...

Dec 27, 2023 07:00 am ET

Algernon Pharmaceuticals Announces Increase to Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces an increase to its non-brokered private placement, previously announced...

Dec 12, 2023 07:42 pm ET

Algernon Pharmaceuticals Announces Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces a non-brokered private placement for gross proceeds of $150,000 (the...

Nov 30, 2023 07:00 am ET

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Nov 22, 2023 07:00 am ET

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

Nov 08, 2023 07:00 am ET

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent...

Sep 06, 2023 07:00 am ET

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the United States Patent and...

Aug 08, 2023 07:00 am ET

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro),...

Jul 14, 2023 06:00 pm ET

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, announces a non-brokered private placement for gross proceeds of CDN$205,000 (the...

Jun 27, 2023 07:00 am ET

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has engaged Maxim Group LLC (“Maxim”) to provide financial...

Jun 06, 2023 07:00 am ET

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at...

Jun 05, 2023 11:43 am ET

Algernon Pharmaceuticals plans Phase 2 stroke and TBI study after successful DMT single dose study

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to provide an update on subsidiary Algernon NeuroScience successfully completing the highest planned single dose of its escalating Phase 1 clinical study of an intravenous formulation of AP-188 or DMT. The company is looking to investigate DMT for treatment of stroke and traumatic brain injury.

Jun 05, 2023 07:00 am ET

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has...

May 31, 2023 11:54 am ET

Algernon gets notice of allowance for patent to treat chronic kidney disease in Japan

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has been granted a patent in Japan for its work around the Compositions and Methods for Treating Chronic Kidney Disease with drug NP-251 or Repirinast.

May 31, 2023 07:19 am ET

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has received a Notice of Allowance from the Japanese Patent...

May 05, 2023 05:00 pm ET

Algernon Pharmaceuticals Announces Closing of Rights Offering

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces that it has closed its previously announced rights offering which expired...

Apr 21, 2023 02:33 pm ET

CSE Bulletin: Expiry - Algernon Pharmaceuticals Inc. - Rights (AGN.RT)

Toronto, Ontario--(Newsfile Corp. - le 21 avril/April 2023) - Algernon Pharmaceuticals Inc. Rights listed on March 28, 2023 will expire on April 27, 2023.

Apr 20, 2023 07:00 am ET

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is reminding its shareholders of the details of its previously announced rights offering...

Apr 18, 2023 10:56 am ET

Algernon Pharmaceuticals receives notice of allowance for US patent for drug Repirinast and NASH

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company has received a Notice of Allowance for a patent around its work on chronic kidney disease.

Apr 17, 2023 07:00 am ET

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce that it has received a Notice of Allowance from the United States...

Apr 05, 2023 11:03 am ET

Algernon NeuroScience reports successful second cohort dosing in DMT clinical study

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon Neuroscience has completed dosing of the second cohort in the Phase 1 clinical study of DMT.

Apr 04, 2023 07:00 am ET

Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has...

Apr 03, 2023 07:00 am ET

Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M

Mar 27, 2023 12:35 pm ET

CSE Bulletin: New Listing - Algernon Pharmaceuticals Inc. 27APRIL2023 Rights

Toronto, Ontario--(Newsfile Corp. - Le 27 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a Rights Offering to eligible shareholders of record at the close of market on March 29, 2023. A holder resident in an Eligible Jurisdiction will be offered one (1) transferable right for each one (1) Share held. Each one (1) Right entitles you to subscribe for one (1) Unit of Algernon at a subscription price of $0.25 per Unit. Each Unit will consist of one Share and one transferable Share purchase warrant. Each Warrant entitles the holder to purchase one additional Share at the exercise price of $0.52.

Mar 21, 2023 07:00 am ET

Algernon Pharmaceuticals Announces Launch of Rights Offering

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces it is undertaking a rights offering to raise gross proceeds of...

Mar 02, 2023 08:00 am ET

Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro) has appointed...

Mar 01, 2023 03:38 pm ET

CSE Bulletin: Stock Split - Algernon Pharmaceuticals Inc. (AGN)

Toronto, Ontario--(Newsfile Corp. - Le 1 mars/March 2023) - Algernon Pharmaceuticals Inc. has announced a four (4) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive three (3) additional shares for each share held on such date.

Feb 28, 2023 08:45 pm ET

Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that effective at the opening of markets on March 3, 2023, the Class A Common...

Feb 21, 2023 07:00 am ET

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro) has added a...

Feb 17, 2023 09:25 am ET

Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT

Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the company’s subsidiary Algernon NeuroScience has announced it has completed the first dosing in its Phase 1 clinical study of an intravenous formulation of AP-188 or DMT.

Feb 16, 2023 07:00 am ET

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has...

Jan 17, 2023 04:00 pm ET

Algernon Pharmaceuticals subsidiary Algernon NeuroScience doses first patient in stroke study

Algernon Pharmaceuticals CEO Christopher Moreau said the company has announced that its subsidiary Algernon NeuroScience has dosed the first subject in the Phase 1 DMT clinical stroke study. Moreau told Proactive this dosing was in the Netherlands where the study is being conducted at the Centre for Human Drug Research in Leiden. The first part of the study will use a single-escalating dose design aimed at identifying a safe and tolerable dose that will not produce psychedelic effects.

Jan 17, 2023 07:00 am ET

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary, Algernon NeuroScience (AGN Neuro),...

Jan 11, 2023 07:00 am ET

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

Jan 10, 2023 12:00 pm ET

Algernon Pharmaceuticals releases details of Phase 2b chronic cough study of Ifenprodil

Algernon Pharmaceuticals CEO Christopher Moreau shared news that the company has announced it is planning a 180 patient, 3-month, Phase 2b clinical study of Ifenprodil for chronic cough. The study is set to begin in Q3 of 2023 and follows positive feedback from the US FDA at its pre-Investigational new drug meeting.

Jan 09, 2023 02:00 pm ET

The Power Play by The Market Herald Releases a New Interview with Algernon Pharmaceuticals Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / January 9, 2023 / The Power Play by The Market Herald has announced the release of a new interview with Algernon Pharmaceuticals discussing their latest news.

Jan 09, 2023 07:00 am ET

Algernon Pharmaceuticals Announces Plans for a 180 Patient Phase 2b Chronic Cough Study of Ifenprodil

Jan 04, 2023 08:00 am ET

Algernon Pharmaceuticals forms Algernon NeuroScience subsidiary to advance DMT stroke program

Proactive Canada

Jan 03, 2023 07:00 am ET

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering

Dec 05, 2022 07:00 am ET

Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Nov 16, 2022 07:00 am ET

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Nov 08, 2022 11:00 am ET

Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.

Oct 24, 2022 07:00 am ET

Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has entered an Investigator-Initiated Clinical Trial...

Oct 14, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Dr. Rick Strassman author of “DMT: The Spirit Molecule” to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that Dr. Rick Strassman, author of the book DMT: The Spirit...

Sep 21, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Receipt of CDN $450K Cash Refund from Australian Research Program

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has recently received a cash payment of...

Sep 19, 2022 07:00 am ET

Algernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF

Sep 12, 2022 07:00 am ET

Algernon Pharmaceuticals Receives Approval for Groundbreaking Phase 1 DMT Human Stroke Study

Sep 08, 2022 07:00 am ET

Algernon Pharmaceuticals Secures Lead Sponsorship of 2022 Wonderland Psychedelic Conference in Miami

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce that it will be the Headline Sponsor for Wonderland, the...

Sep 08, 2022 07:00 am ET

Microdose Announces Algernon Pharmaceuticals as Wonderland's Headline Sponsor

Miami, Florida--(Newsfile Corp. - September 8, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is thrilled to announce Algernon Pharmaceuticals (CSE: AGN) (FSE: AGW0) (OTCQB: AGNPF) ("Algernon") as the official Headline Sponsor for Wonderland, the world-leading event in the psychedelic medicine industry. The highly anticipated gathering is coming back to Miami from November 3-5th, 2022, at the Mana Wynwood Convention Centre in Miami's Arts and Entertainment District. The Algernon's CEO, Christopher J. Moreau, will deliver two keynote addresses:

Sep 01, 2022 03:20 pm ET

The Power Play by The Market Herald Releases New Interviews with Algernon, Permex Petroleum, Infinity Stone, Green River Gold, HIRE Technologies, and Aton Resources Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / September 1, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Algernon, Permex Petroleum, Infinity Stone, Green River Gold, HIRE Technologies, and Aton Resources discussing their latest news.

Sep 01, 2022 07:00 am ET

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to report positive results from the full data set of its Phase 2a Study...

Aug 23, 2022 07:15 am ET

Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that its largest shareholder, AlphaNorth Asset Management (“AlphaNorth”), has increased its ownership position in the...

Aug 23, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Closing of Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce it has closed its previously announced non-brokered private placement...

Aug 18, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce a non-brokered private placement for gross proceeds of $1,402,125...

Aug 03, 2022 07:07 am ET

Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase...

Jul 28, 2022 07:00 am ET

Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce additional results from its Phase 2a Study of NP-120...

Jul 18, 2022 03:30 pm ET

The Power Play by The Market Herald Releases New Interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove, and Orvana Minerals

VANCOUVER, BC / ACCESSWIRE / July 18, 2022 / The Power Play by The Market Herald has announced the release of new interviews with First Mining Gold Corp., Algernon Pharmaceuticals, G Mining Ventures, ApartmentLove, and Orvana Minerals on their latest news.

Jul 18, 2022 08:43 am ET

IIROC Trade Resumption - AGN

VANCOUVER, BC, July 18, 2022 /CNW/ - Trading resumes in:

Jul 18, 2022 08:00 am ET

Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce positive topline data showing that it has met the...

Jul 15, 2022 10:12 am ET

IIROC Trading Halt - AGN

VANCOUVER, BC, July 15, 2022 /CNW/ - The following issues have been halted by IIROC:

Jul 11, 2022 07:00 am ET

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (“CKD”) research...

Jul 07, 2022 03:35 pm ET

The Power Play by The Market Herald Releases New Interviews with K9 Gold, Algernon Pharmaceuticals, Deep-South Resources, and Saturn Oil & Gas

VANCOUVER, BC / ACCESSWIRE / July 7, 2022 / The Power Play by The Market Herald has announced the release of new interviews with K9 Gold, Algernon Pharmaceuticals, Deep-South Resources, and Saturn Oil & Gas on their latest news.

Jul 07, 2022 07:00 am ET

Algernon Pharmaceuticals Provides Update on Its Phase 1 DMT Stroke Study

Jul 05, 2022 07:00 am ET

Algernon Pharmaceuticals Discloses Novel DMT Salt Patent Strategy Includes Bioactive Nicotinate and Pamoate

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patent applications filed...

Jul 04, 2022 11:14 am ET

Algernon Pharmaceuticals Announces Closing of Public Offering of Units

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce the closing of its previously announced marketed public offering of units of the Company (the “Units” or the “Offered...

Jun 27, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Pricing of Public Offering of Units

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce the price of its previously announced marketed public offering of units of the Company (the “Units” or the “Offered...

Jun 22, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Issuance of Patent for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has been issued a patent from the Canadian...

Jun 21, 2022 07:00 am ET

Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, announces that patients from multiple sites participating in its Phase 2 proof of...

Jun 15, 2022 04:53 pm ET

Algernon Pharmaceuticals Announces Public Offering of Units

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is pleased to announce that it is undertaking a marketed public offering of units of the Company (the “Units” or the “Offered Securities”) with...

Jun 13, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its Phase 2 proof-of-concept study of NP-120 (“Ifenprodil”) for...

May 05, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that the last patient has completed the treatment period in its Phase...

Apr 26, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that its lead chronic kidney disease (“CKD”) drug NP-251...

Feb 23, 2022 01:45 pm ET

The Power Play by The Market Herald Releases New Interviews With Algernon Pharmaceuticals, Adastra Holdings and C3 Metals

VANCOUVER, BC / ACCESSWIRE/ February 23, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Algernon Pharmaceuticals, Adastra Holdings and C3 Metals on their latest news.

Feb 23, 2022 07:00 am ET

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has awarded a contract to Zhejiang Ausun Pharmaceutical CO,...

Feb 04, 2022 07:00 am ET

Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has completed enrollment in its Phase 2 NP-120...

Jan 28, 2022 06:00 am ET

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Canadian Patent...

Jan 24, 2022 02:05 pm ET

The Power Play by The Market Herald Releases Interviews with Algernon Pharmaceuticals, Newrange Gold, and Fokus Mining

VANCOUVER, BC / ACCESSWIRE / January 24, 2022 / The Power Play by The Market Herald has announced the release of a new interviews with Algernon Pharmaceuticals, Newrange Gold, and Fokus Mining discussing their latest press releases.

Jan 24, 2022 07:00 am ET

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to disclose that as part of its intellectual property patent applications filed...

Jan 19, 2022 02:55 pm ET

The Power Play by The Market Herald Releases Interviews With Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals

VANCOUVER, BC / ACCESSWIRE / January 19, 2022 / The Power Play by The Market Herald has announced the release of new interviews with Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals discussing their latest press releases.

Jan 19, 2022 07:00 am ET

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has filed a combined Clinical Trials of Investigational...

Jan 14, 2022 03:05 pm ET

The Power Play by The Market Herald Releases Interview with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical

VANCOUVER, BC / ACCESSWIRE / January 14, 2022 / The Power Play by The Market Herald has announced the release of new interviews with EarthRenew, Algernon Pharmaceuticals and Rockwell Medical discussing their latest press releases.

Jan 14, 2022 08:15 am ET

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 2b Ifenprodil Chronic Cough Study

Jan 04, 2022 09:15 am ET

Algernon Pharmaceuticals Issues Compensation Options

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company reports that the Company has granted 96,000 stock options exercisable at $4.10 for five years...

Dec 08, 2021 07:04 am ET

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply...

Dec 02, 2021 07:00 am ET

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has added a clinical trial site in Australia for its ongoing...

Nov 30, 2021 07:00 am ET

Algernon Pharmaceuticals Announces New Chief Financial Officer

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Mr. James Kinley as the Company’s Chief...

Nov 24, 2021 07:00 am ET

Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA for Phase 1 Ifenprodil Small Cell Lung Cancer Study

Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has received positive feedback from the U.S. Food and Drug...

Nov 23, 2021 04:01 pm ET

Algernon Pharmaceuticals Announces Effective Date of Previously Announced Share Consolidation

Algernon Pharmaceuticals Inc. (“Algernon” or the “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical development company, announces that effective November 24, 2021, the Company will consolidate its Class A common...

Nov 19, 2021 02:00 pm ET

The Power Play by The Market Herald Interviews Christopher Moreau of Algernon Pharmaceuticals Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / November 19, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Algernon Pharmaceuticals discussing their latest press release.

Nov 19, 2021 07:00 am ET

Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT Human Stroke Study

Nov 18, 2021 02:37 pm ET

CSE Bulletin: Consolidation - Algernon Pharmaceuticals Inc. (AGN)

Toronto, Ontario--(Newsfile Corp. - Le 18 novembre/November 2021)

Nov 17, 2021 04:14 pm ET

Algernon Pharmaceuticals Announces Share Consolidation

Algernon Pharmaceuticals Inc. (“Algernon” or “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical development company, announces that it intends to consolidate its Class A common shares (the “Common Shares”) on a...

Nov 01, 2021 03:25 pm ET

The Power Play by The Market Herald Releases New Interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals Discussing Their Latest News

VANCOUVER, BC / ACCESSWIRE / November 1, 2021 / The Power Play by The Market Herald has announced the release of new interviews with Datametrex, Group Ten Metals, Algernon Pharmaceuticals and Alianza Minerals discussing their latest press releases.

Nov 01, 2021 07:00 am ET

Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment Period for DMT in Neuron Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has established the optimum peak stimulation period of 6...

Oct 21, 2021 07:00 am ET

Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund from Australian Research Program and Files Application to List its Common Shares on Nasdaq Capital Market

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has recently received a CAD$2M cash payment from a...

Oct 15, 2021 12:00 pm ET

The Power Play by The Market Herald Announces Interviews with Algernon Pharmaceuticals, NextechAR, UCore Rare Metals, Falcon Gold, and Durango Resources on Latest Company News

VANCOUVER, BC / ACCESSWIRE / October 15, 2021 / The Market Herald, the leading source of authoritative breaking stock market news for self-directed investors spoke with Algernon Pharmaceuticals, UCore Rare Metals Inc., Nextech AR Solutions, Falcon Gold Corp., and Durango Resources Inc. about their latest company news.

Oct 13, 2021 07:00 am ET

Algernon Files Meeting Request with MHRA for Use of DMT in Phase 1/2a Human Stroke Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has filed a scientific advice meeting request with the United...

Oct 08, 2021 07:00 am ET

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Chronic Cough Phase 2 Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has filed a pre-IND (Investigational New Drug) meeting request...

Oct 05, 2021 07:00 am ET

Hagens Berman: Law Firm Investigating Permanent Injuries and Disfigurement from Botched CoolSculpting Procedures

Consumer-rights and personal injury law firm Hagens Berman has launched a nationwide investigation into CoolSculpting regarding the risk of permanent disfigurement and serious harm to patients’ bodies following treatment, which can include paradoxical adipose hyperplasia (PAH).

Sep 22, 2021 07:30 am ET

Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request for Ifenprodil Small Cell Lung Cancer Study

Sep 22, 2021 07:00 am ET

Algernon Pharmaceuticals Announces the Appointment of Dr. Mark Williams to the Board of Directors

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board...

Sep 20, 2021 07:00 am ET

Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil Chronic Cough Study in the U.S.

Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) (FRANKFURT: AGW) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to file a pre-IND (Investigational New Drug) meeting...

Sep 09, 2021 11:46 am ET

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau will be delivering the Keynote...

Sep 09, 2021 07:00 am ET

Algernon Pharmaceuticals Announces Appointment of Harry Bloomfield, QC. as a New Board Director and Chairman

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that Harry Bloomfield, QC. has been appointed as a new member of the...

Sep 07, 2021 07:30 am ET

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study, that AP-188...

Sep 01, 2021 08:06 am ET

Leading DMT Companies to Take Stage at Molecular Masterclass: DMT Conference

Get a free ticket to the event here: https://microdose.buzz/nwdmt

Aug 30, 2021 09:35 am ET

Microdose Psychedelic Insights Presents the Upcoming DMT Conference, a Deep Dive Into the Dynamic Field of DMT Therapeutics

via NetworkNewsWire -- Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be...

Aug 11, 2021 07:00 am ET

Algernon Pharmaceuticals Announces Small Cell Lung Cancer Ifenprodil Research Program and Appoints Dr. William North as Lead Consultant

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has initiated an NP-120 (“Ifenprodil”) small cell lung cancer...

Aug 09, 2021 07:00 am ET

Algernon Pharmaceuticals Announces Exclusive Licensing Agreement with Dartmouth College

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has signed an exclusive licensing agreement with Dartmouth...

Jul 27, 2021 07:00 am ET

Microdose Is Pleased to Announce the DMT Conference: A Molecular Masterclass

Get a free ticket to the event here: https://microdose.buzz/nwdmt

Jul 07, 2021 07:30 am ET

Algernon Pharmaceuticals Announces 70% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, announces that it has reached 70% of its enrollment target for its Phase 2 clinical study of...

Jul 06, 2021 08:30 am ET

Algernon Pharmaceuticals Announces it Will Not Advance Ifenprodil into Phase 3 Trial for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it will not be advancing Ifenprodil into a Phase 3 clinical study for...

Jun 17, 2021 07:00 am ET

Algernon Pharmaceuticals Targets First Human Study of its Psychedelic Drug DMT Stroke Program for Q4, 2021

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to announce that all of the required permits and licenses for the manufacture of its cGMP supply of AP-188 (“N, N-Dimethyltryptamine...

Jun 03, 2021 07:00 am ET

Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical Research Program with Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has initiated a new clinical research program for pancreatic cancer (PC) and NP-120 (Ifenprodil). Ifenprodil demonstrated a...

May 27, 2021 07:00 am ET

Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an independent research study from the University of Szeged in Hungary describing the use of N,N-dimethyltryptamine...

May 17, 2021 07:00 am ET

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its plans to investigate AP-188...

May 12, 2021 07:15 am ET

Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin 6 in Phase 2b/3 COVID Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin 6 (IL-6) with statistical significance...

May 11, 2021 07:01 am ET

Algernon Pharmaceuticals Announces 50% Enrollment of its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has reached 50% of its enrollment target for its Phase 2...

Apr 26, 2021 08:00 am ET

Algernon Pharmaceuticals Files End of Phase 2 Meeting Request with U.S. FDA for its COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, announces that it has filed an end of Phase 2 meeting request (EOP2) with the U.S. Food and...

Apr 08, 2021 07:00 am ET

Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request with U.S. FDA for Possible Ifenprodil Phase 3 COVID-19 Trial

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to formalize discussions with the U.S. Food and Drug...

Apr 06, 2021 08:00 am ET

Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has appointed Dr. Steven L. Wolf, a global expert in the...

Mar 31, 2021 08:00 am ET

Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce topline data from the Phase 2b part of its Phase 2b/3 COVID-19 trial...

Mar 29, 2021 07:02 am ET

Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF...

Mar 17, 2021 07:00 am ET

Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has filed a pre-IND (Investigational New Drug) meeting...

Mar 11, 2021 07:41 am ET

Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, announces that it expects to report its topline results for the Phase 2b part of its Phase...

Mar 05, 2021 07:31 pm ET

Algernon Pharmaceuticals Announces Increase and Close of Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has increased and completed its previously announced...

Mar 03, 2021 08:00 am ET

Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and DMT Consultant Dr....

Mar 02, 2021 10:18 pm ET

Algernon Pharmaceuticals Announces Private Placement

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce a non-brokered private placement of 10,800,000 units for total...

Mar 01, 2021 08:00 am ET

Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that it has awarded the contract for its Phase 1 stroke program study of AP-188...

Mar 01, 2021 07:00 am ET

Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Dr. Christopher Bryan PhD as Vice President,...

Feb 25, 2021 07:00 am ET

Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau as well as Dr. David Nutt, one of...

Feb 19, 2021 08:00 am ET

Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, announces that it has awarded the contract to manufacture the active pharmaceutical...

Feb 17, 2021 07:47 am ET

Algernon Pharmaceuticals Provides Update on COVID-19 Phase 2b Final Study Data

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide an update on the final data set of the Phase 2b part of the Phase 2b/3...

Feb 11, 2021 02:37 pm ET

BTV News Alert Video: Algernon Pharmaceuticals Inc. - Trial Complete for COVID-19 Treatment

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2021) - Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) - The company has concluded a trial for Ifenprodil and is expecting to report on the data by the end of February. They are hopeful that Ifenprodil will be found to reduce the severity and the duration of a COVID-19 infection.

Feb 10, 2021 07:00 am ET

Algernon Pharmaceuticals Considers Adding Lung Scarring as an Additional Endpoint for its Phase 2b/3 COVID-19 Study Protocol

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has decided to review its protocol for its phase 2b/3 study of...

Feb 08, 2021 08:05 am ET

Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that is has signed an agreement with Charles River Laboratories for...

Feb 03, 2021 08:00 am ET

Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams,...

Feb 01, 2021 07:30 am ET

Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT “The Spirit Molecule”

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it has established a clinical research program for the treatment...

Jan 22, 2021 12:14 pm ET

Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company...

Jan 19, 2021 11:59 am ET

Algernon Pharmaceuticals Provides Reminder on Expiry Date of Accelerated Warrants

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a reminder to the market that the common share purchase warrants of the...

Jan 19, 2021 08:03 am ET

Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (“DSMB”) has...

Jan 11, 2021 08:00 am ET

Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research review (the “Review”) published in the...

Jan 07, 2021 08:00 am ET

Algernon Pharmaceuticals Announces Plans for 2021

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide an overview of the Company’s primary plans for the upcoming calendar...

Dec 30, 2020 08:00 am ET

Algernon Pharmaceuticals Provides Year End Summary of Key Activities

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year....

Dec 24, 2020 11:42 am ET

Algernon Pharmaceuticals Announces Last Patient Out in Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the last patient from the Phase 2b part of its multinational...

Dec 23, 2020 07:40 pm ET

Algernon Pharmaceuticals Announces Acceleration of Expiry Date of Warrants

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that the Company has elected to exercise its acceleration right under the warrant...

Dec 21, 2020 08:00 am ET

Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams,...

Dec 17, 2020 08:00 am ET

Algernon Pharmaceuticals Provides Additional Information on Phase 2b/3 Ifenprodil COVID-19 Study Interim Data

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to provide additional information on its interim data report for the Phase 2b...

Dec 16, 2020 07:43 pm ET

Algernon CEO and CSO to Discuss COVID-19 Interim Data Results Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Algernon’s CEO Christopher J. Moreau and CSO Dr. Mark Williams,...

Dec 15, 2020 08:29 am ET

IIROC Trade Resumption - AGN

VANCOUVER, BC, Dec. 15, 2020 /CNW/ - Trading resumes in:

Dec 15, 2020 08:15 am ET

Algernon Pharmaceuticals Announces Positive Trending Interim Data for its Phase 2b/3 Ifenprodil COVID Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase...

Dec 14, 2020 01:15 pm ET

IIROC Trading Halt - AGN

VANCOUVER, BC, Dec. 14, 2020 /CNW/ - The following issues have been halted by IIROC:

Nov 30, 2020 08:00 am ET

Algernon Pharmaceuticals Announces Enrollment of Final Patient in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the final patient has been enrolled in its multinational Phase...

Nov 23, 2020 07:30 am ET

Algernon Pharmaceuticals Announces 154 Patients Enrolled in its Multinational Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 154 patients in its multinational Phase 2b/3...

Nov 16, 2020 08:00 am ET

Algernon Pharmaceuticals Announces Receipt of Refundable Tax Credit from Australian Clinical Research

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it has recently received approximately $600,000 CDN in the form...

Nov 13, 2020 08:00 am ET

Algernon Pharmaceuticals Provides Update on its Ifenprodil Phase 2 Clinical Trials Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil Phase 2 human...

Nov 09, 2020 08:00 am ET

Algernon Pharmaceuticals Announces Plans to Provide Interim Data from its Ifenprodil Phase 2b/3 COVID-19 Human Study

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it plans to conduct an interim data review of its multi-national...

Oct 30, 2020 08:00 am ET

Algernon Pharmaceuticals Announces Green Light From Data and Safety Monitoring Board to Continue its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that after its second meeting and review, the external Data and...

Oct 13, 2020 08:00 am ET

Algernon Pharmaceuticals Announces 25% Enrollment in its Ifenprodil IPF and Chronic Cough Phase 2 Human Study

Oct 09, 2020 08:00 am ET

Algernon Pharmaceuticals Appoints Dr. Mark Swaim MD, PhD to its Medical and Scientific Advisory Board

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that Dr. Mark Swaim, a former practicing physician and researcher has...

Oct 02, 2020 08:40 am ET

Algernon Announces 75% Enrollment in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75% of its enrollment target, which is 113...

Sep 29, 2020 08:00 am ET

Algernon Announces Enrollment of 100 Patients in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 100 patients, which is two thirds of its...

Sep 22, 2020 08:00 am ET

Algernon Announces 50% Enrollment in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75 patients, which is 50% of its enrollment...

Sep 16, 2020 08:00 am ET

Algernon Announces Data and Safety Monitoring Board Recommends the Continuation of its Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (DSMB) has...

Sep 02, 2020 08:31 am ET

Algernon Announces Enrollment of 50th Patient in Multinational 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 50 patients in its multinational Phase 2b/3...

Aug 25, 2020 01:40 pm ET

Algernon Pharmaceuticals Inc., Next Phase Study of Ifenprodil for COVID-19 Treatment, CEO Clip Video

Vancouver, British Columbia--(Newsfile Corp. - August 25, 2020) - Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF) CEO of Algernon Pharmaceuticals, Christopher Moreau, speaks about the Company's phase 2b/3 multinational study of Ifenprodil as a potential therapeutic for COVID-19.

Aug 25, 2020 08:00 am ET

Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough Phase 2 Human Study Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil idiopathic...

Aug 24, 2020 12:36 pm ET

Algernon Updates Market on Analyst Coverage by Mackie Research

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is providing the clarification that the recently published report on the Company initiated...

Aug 24, 2020 07:00 am ET

Algernon Announces Research Analyst Coverage by Mackie Research with an $0.80/share Target Price

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that research on the Company has been initiated by André Uddin,...

Aug 17, 2020 08:00 am ET

Algernon CEO Presents Corporate Update Featured on BioPub Webcast Hosted by Dr. KSS MD PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical development company, is pleased to announce that Christopher J. Moreau, CEO of Algernon, will be providing an...

Aug 13, 2020 08:15 am ET

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Aug 05, 2020 02:24 pm ET

IIROC Trade Resumption - AGN

VANCOUVER, BC, Aug. 5, 2020 /CNW/ - Trading resumes in:

Aug 05, 2020 01:57 pm ET

Algernon Announces Enrollment of First Patient in 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient in its multinational Phase...

Aug 05, 2020 01:29 pm ET

IIROC Trading Halt - AGN

VANCOUVER, BC, Aug. 5, 2020 /CNW/ - The following issues have been halted by IIROC:

Aug 05, 2020 08:37 am ET

Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic Cough Human Trial of Ifenprodil

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the first patient has been dosed in its Phase 2 idiopathic...

Jul 21, 2020 08:00 am ET

Algernon Highlights UT Dallas Research Study Identifying Ifenprodil as a Possible COVID-19 Treatment

Jul 16, 2020 08:00 am ET

Algernon Announces First U.S. Clinical Trial Site in Florida for Phase 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has completed its clinical trial agreement with Westchester...

Jul 07, 2020 08:00 am ET

Algernon Begins Screening Patients for Phase 2 Ifenprodil IPF and Chronic Cough Human Study in Australia

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has begun screening patients for suitability for enrolment in...

Jul 06, 2020 09:49 pm ET

Algernon Pharmaceuticals Announces Extension of Exercise Date of Warrants

Algernon Pharmaceuticals Inc. (“Algernon” or “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical development company, announces that it has extended 4,000,000 warrants originally expiring on July 18, 2020 (the...

Jun 25, 2020 08:00 am ET

Algernon Receives Ethics Approval for U.S. Sites for 2b/3 Human Study of Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has received ethics approval from a central institutional...

Jun 12, 2020 05:07 pm ET

Algernon Pharmaceuticals Announces Deemed Exercise of Special Warrants

Algernon Pharmaceuticals Inc. (“Algernon” or “Company”) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical development company, is pleased to announce today that it has received a receipt for the Company’s final short form...

Jun 04, 2020 12:41 pm ET

IIROC Trade Resumption - AGN

VANCOUVER, BC, June 4, 2020 /CNW/ - Trading resumes in:

Jun 04, 2020 12:11 pm ET

Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has received, on June 3rd, 2020, clearance from the U.S. FDA...

Jun 04, 2020 08:04 am ET

IIROC Trading Halt - AGN

VANCOUVER, BC, June 4, 2020 /CNW/ - The following issues have been halted by IIROC:

May 28, 2020 09:00 am ET

Algernon Pharmaceuticals Discusses Multinational Phase 2b/3 Ifenprodil COVID-19 Human Trial on BioPub Webcast Hosted by Dr. KSS MD PhD

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce that it will be featured on an upcoming BioPub webcast hosted by Dr....

May 26, 2020 08:49 am ET

Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has submitted an Investigational New Drug (IND) application...

May 25, 2020 08:00 am ET

Algernon Submits Investigational New Drug (IND) Application with U.S. FDA for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil for COVID-19

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that it has submitted an Investigational New Drug (IND) application...

May 15, 2020 08:30 am ET

Ad blocking detected

Algernon Pharmaceuticals Inc. (C:AGN)

Business Focus: Bio Therapeutic Drugs